eFFECTOR Therapeutics Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Craig Jalbert

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Craig Jalbert (62 yo)

less than a year

Mandato

Mr. Craig R. Jalbert is President, Treasurer, CS, Principal Executive Officer, Financial Officer, & Principal Accounting Officer of NexImmune, Inc. from August 27, 2024 He is Chief Executive Officer, Presi...

eFFECTOR Therapeutics Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

eFFECTOR Therapeutics, Inc. Appoints Caroline Loewy to its Board of Directors

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 22, 2023

High number of new directors

High number of new directors

High number of new directors

Recent updates

eFFECTOR Therapeutics Files Form 15

eFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index

eFFECTOR Therapeutics Provides Non-Compliance Update

eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term

eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term

eFFECTOR Therapeutics, Inc. Receives Written Notice from Nasdaq Regarding Minimum Value of Listed Securities

New major risk - Revenue and earnings growth

eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

New major risk - Market cap size

eFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.000003 million.

eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.000003 million.

eFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients

eFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer

New major risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.23 loss in 3Q 2022)

Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia (Aml)

eFFECTOR Therapeutics, Inc. Appoints Caroline Loewy to its Board of Directors

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq Stock Market Regarding Non-Compliance with Nasdaq's Minimum Bid Price Requirement

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.733186 million.

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million.

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million.

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 22, 2023

High number of new directors

High number of new directors

eFFECTOR Therapeutics, Inc. Provides Positive Clinical Data Update for Zotatifin and General Corporate Update

High number of new directors

High number of new directors

Effector Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1B Clinical Trial of Zotatifin for the Treatment of Covid-19

High number of new directors

Effector Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

eFFECTOR Therapeutics, Inc. Doses First Patient in Second Cohort of Phase 1B Clinical Trial of Zotatifin for the Treatment of Covid-19

eFFECTOR Therapeutics Receives A Letter from the Nasdaq Stock Market Staff

eFFECTOR Therapeutics Appoints Douglas Warner as Chief Medical Officer

eFFECTOR Therapeutics, Inc. Announces Executive Changes

Investor sentiment deteriorated over the past week

eFFECTOR Therapeutics, Inc. Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity

Investor sentiment improved over the past week

eFFECTOR Therapeutics, Inc. Announces Interim Data from Its Ongoing Phase 1/2 Clinical Trial of Zotatifin in Solid Tumors

Investor sentiment deteriorated over the past week

High number of new directors

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

eFFECTOR Therapeutics, Inc. Announces Transition in Clinical Leadership

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

eFFECTOR Therapeutics, Inc. Announces Directorate Changes

eFFECTOR Therapeutics, Inc. Provides Pipeline and Business Updates

High number of new directors

Independent Director recently sold €420k worth of stock

Independent Director recently sold €366k worth of stock

eFFECTOR Therapeutics, Inc. Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

Independent Director recently sold €362k worth of stock

Independent Director recently sold €196k worth of stock

Independent Director recently sold €801k worth of stock

Third quarter 2021 earnings released: EPS US$0.53

AMMINISTRATORE DELEGATO

Mandato